NanoVibronix receives Nasdaq delisting notice for failure to meet $1.00 bid price

ENvue Medical, Inc.

Failed to regain compliance with $1.00 minimum bid price by Oct 7, 2024; Nasdaq notified Oct 8.
Company will request a hearing before Nasdaq Hearings Panel, which will stay delisting action pending hearing.
No guarantee that the Panel will grant continued listing or an extension of time to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.